{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:57:49Z","timestamp":1777111069451,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.clinthera.2015.08.024","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T05:59:28Z","timestamp":1443333568000},"page":"2458-2467","source":"Crossref","is-referenced-by-count":13,"title":["Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct02481583","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mingzhen","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huqun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haseeb","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.08.024_bib1","series-title":"The Complete Drug Reference","first-page":"119","author":"Sweetman","year":"2007"},{"key":"10.1016\/j.clinthera.2015.08.024_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/tcrm.2007.3.1.149","article-title":"Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia","volume":"3","author":"Lozano","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"10.1016\/j.clinthera.2015.08.024_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2036.1994.tb00341.x","article-title":"The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia","volume":"8","author":"Arienti","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.08.024_bib4","first-page":"317","article-title":"Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial","volume":"28","author":"Corazza","year":"1996","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.clinthera.2015.08.024_bib5","first-page":"655","article-title":"Sulpiride: The best known atypical, safe neuroleptic drug. Review of literature","volume":"32","author":"Rzewuska","year":"1998","journal-title":"Psychiatr Pol"},{"key":"10.1016\/j.clinthera.2015.08.024_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01983482","article-title":"Gastric and duodenal anti-ulcer activity of sulpiride, a dopamine D2 receptor antagonist, in rats","volume":"42","author":"Desai","year":"1994","journal-title":"Agents Actions"},{"key":"10.1016\/j.clinthera.2015.08.024_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2165\/00002018-199614050-00003","article-title":"A risk-benefit assessment of sulpiride in the treatment of schizophrenia","volume":"14","author":"Mauri","year":"1996","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2015.08.024_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/1043-6618(95)80053-0","article-title":"Levosulpiride: a review of its clinical use in psychiatry","volume":"31","author":"Mucci","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clinthera.2015.08.024_bib9","series-title":"Psychopharmacology: The Fourth Generation of Progress","first-page":"295","article-title":"Dopamine receptors: Clinical correlates","author":"Seeman","year":"1995"},{"key":"10.1016\/j.clinthera.2015.08.024_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02245639","article-title":"Chronic administration of l-sulpiride at non-neuroleptic doses reduces the duration of immobility on experimental models of depression-like behavior","volume":"121","author":"Vergoni","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.clinthera.2015.08.024_bib11","first-page":"40","article-title":"La levosulpiride nei disturbi affettivi minori, d,ansia e somatoformi: confronto di attivita in cross-over con sulpiride racema","volume":"10","author":"Perbellini","year":"1989","journal-title":"Giornale Neuropsicofarmacologia"},{"key":"10.1016\/j.clinthera.2015.08.024_bib12","first-page":"485","article-title":"Synthesis of Levosulpiride","volume":"27","author":"Zhongliang","year":"1996","journal-title":"Chin J Pharm"},{"key":"10.1016\/j.clinthera.2015.08.024_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.apsb.2014.06.001","article-title":"Pharmacokinetics of levosulpiride after single and multiple intramuscular administrations in healthy Chinese volunteers","volume":"4","author":"Gong","year":"2014","journal-title":"Acta Pharm Sinica B"},{"key":"10.1016\/j.clinthera.2015.08.024_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF00558453","article-title":"The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects","volume":"17","author":"Wiesel","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.08.024_bib15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/jps.2600801206","article-title":"Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations","volume":"80","author":"Br\u00e9s","year":"1991","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2015.08.024_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/bdd.1843","article-title":"Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double-peak absorption profile after oral administration to human volunteers","volume":"34","author":"Helmy","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.clinthera.2015.08.024_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-15194","article-title":"Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study","volume":"34","author":"M\u00fcller","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinthera.2015.08.024_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.neuroscience.2010.04.065","article-title":"Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects","volume":"169","author":"Cho","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.clinthera.2015.08.024_bib19","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. http:\/\/jama.jamanetwork.com\/article.aspx?articleid=1760318. Accessed 2013."},{"key":"10.1016\/j.clinthera.2015.08.024_bib20","unstructured":"Ravizza Farmaceutici. Pharmacokinetics of l-sulpiride after single i.v., i.m. and oral administration in humans. Internal Report, 1989"},{"key":"10.1016\/j.clinthera.2015.08.024_bib21","unstructured":"Ravizza Farmaceutici. Comparative pharmacokinetic study of l-sulpiride (25 and 50 mg) and d,l-sulpiride (50 and 100 mg) after single oral administration to humans. Internal Report, 1990"},{"issue":"5","key":"10.1016\/j.clinthera.2015.08.024_bib22","first-page":"239","article-title":"Effetto antiemetico dell\u2019isomero levogiro della sulpiride (l-sulpiride) nell\u2019uomo","volume":"55","author":"Schettini","year":"1989","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.clinthera.2015.08.024_bib23","first-page":"974","article-title":"A randomized crossover clinical study on the effectiveness of L-sulpiride in the prevention of nausea and emesis induced by antiblastic chemotherapy","volume":"46","author":"De Jong","year":"1989","journal-title":"Curr Ther Res Clin Exp"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:22:39Z","timestamp":1537316559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815010978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0149291815010978"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.08.024","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}